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Abstract
Introduction: Globally, increasing numbers of HIV-infected children are reaching adolescence due to antiretroviral therapy
(ART). We investigated rates of loss-to-follow-up (LTFU) from HIV care services among children as they transition from
childhood through adolescence.
Methods: Individuals aged 5–19 years initiated on ART in a public-sector HIV clinic in Bulawayo, Zimbabwe, between 2005
and 2009 were included in a retrospective cohort study. Participants were categorized into narrow age-bands namely: 5–9
(children), 10–14 (young adolescents) and 15–19 (older adolescents). The effect of age at ART initiation, current age (using a
time-updated Lexis expansion) and transitioning from one age group to the next on LTFU was estimated using Poisson
regression.
Results: Of 2273 participants, 1013, 875 and 385 initiated ART aged 5–9, 10–14 and 15–19 years, respectively. Unlike those
starting ART as children, individuals starting ART as young adolescents had higher LTFU rates after moving to the older
adolescent age-band (Adjusted rate ratio (ARR) 1.54; 95% CI: 0.94–2.55) and similarly, older adolescents had higher LTFU
rates after transitioning to being young adults (ARR 1.79; 95% CI: 1.05–3.07). In older adolescents, the LTFU rate among
those who started ART in that age-band was higher compared to the rate among those starting ART at a younger age
(ARR = 1.70; 95% CI: 1.05, 2.77). This however did not hold true for other age-groups.
Conclusions: Adolescents had higher rates of LTFU compared to other age-groups, with older adolescents at particularly high
risk in all analyses. Age-updated analyses that examine movement across narrow age-bands are paramount in understanding
how developmental heterogeneity in children affects HIV outcomes.
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Introduction
In 2015, there were 2 million adolescents aged 10–19
living with HIV worldwide [1]. The remarkable scale-up of
paediatric antiretroviral therapy (ART) globally has
resulted in increasing numbers of infants infected with
HIV surviving to adolescence and beyond; and the num-
ber of HIV-infected adolescents is projected to continue
increasing for at least a decade [2]. The scale-up of
prevention of mother-to-child HIV transmission pro-
grammes started in 2005 resulting in a 75% decrease in
new paediatric HIV infections globally [1]. Despite this
success, an estimated 150,000 children (aged 0–14 years)
were newly infected with HIV in 2015, nearly 85% of
them in sub-Saharan Africa. Many of these children will
present to healthcare services in adolescence [3].
Despite the significant disease burden in this age group,
adolescents living with HIV fall through the gaps of poorly
coordinated health systems and HIV programmes that have
focused on adults, infants and young children. Research
studies and programmes often exclude adolescents or
group them with children and adults (e.g. 0–15 years, 15+
years) [4]. If age-stratified analyses are conducted, indivi-
duals are usually categorized by age at ART initiation, an
approach widely used for adult ART cohorts [4]. Most
cohort analyses of HIV-infected children and adolescents
do not consider the significant heterogeneity in develop-
ment across this age group or the impact of the phase of
rapid physical and psychosocial development during adoles-
cence. Therefore, longitudinal analyses investigating HIV
care outcomes that stratify children based on age at ART
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initiation will fail to account for the impact of developmen-
tal changes on health outcomes.
We conducted a cohort study of older children, ado-
lescents and young adults on ART in Zimbabwe. The
study aimed to investigate outcomes using narrow five-
year age-bands and specifically investigated the effect
of current age and moving into the next age-band on
loss to follow-up (LTFU) rates.
Methods
Study setting and population
Zimbabwe experienced an early onset HIV epidemic with
antenatal HIV prevalence peaking at 30% in 1997. The HIV
incidence has subsequently declined but HIV prevalence
remains high (HIV prevalence among adults in 2015 at
15%). During the period of this study, Zimbabwe experi-
enced massive hyperinflation, a shrinking economy and
food shortages.
Participants were patients who initiated ART aged
5–19 years between 1 January 2005 and 31 December
2009 at the Mpilo Central Hospital HIV clinic in Bulawayo,
the second largest city in Zimbabwe. The Mpilo clinic
started to provide ART in April 2004, the first public sector
facility to do so in Zimbabwe. It has therefore accumulated
a large cohort of adults and paediatric patients on ART with
long periods of follow-up. Details about the operation of
the clinic are given elsewhere [5], but briefly HIV care at the
clinic was provided by the government of Zimbabwe with
several partners including Medecins Sans Frontieres. HIV
treatment was provided in accordance with Zimbabwean
National Guidelines, with individuals eligible for ART if they
had a CD4+ cell count less than 200cells/μl and/or WHO
stage III or IV HIV disease. HIV care was provided free of
charge. Each clinic visit and the individual’s next scheduled
visit were routinely recorded using FUCHIA software
(Epicentre, Paris, France). ART refill visits were scheduled
monthly for the first three months on ART and three
monthly thereafter. Patients were seen by nurses or doc-
tors before they were sent to pick up the drugs. Systematic
tracing of defaulting ART patients, defined as having missed
a scheduled appointment by more than two months, was
done by community volunteers through home visits and
telephone calls. Community volunteers also recorded
death. In addition, mortality data were obtained through
notification by family and through death register review.
Longitudinal patient data were analysed from time of ART
initiation up to 31 December 2010 to allow at least one
year of follow-up.
Data analysis
Data were analysed using STATA version 14 (STATA cor-
poration, Texas, USA). The primary endpoint was time to
LTFU after ART initiation. LTFU was defined as being late for
an appointment for more than 60 days (i.e. the date of the
next scheduled appointment plus 60 days) at the date of
censoring (31 December 2010). The date of LTFU was set at
the date of the next appointment. Death and transfer outs
were treated as censoring events. Baseline characteristics
stratified by age group were described by frequencies for
categorical variables. CD4 count at initiation of ART was
summarized as medians and inter-quartile range.
Age was the explanatory variable of interest.
Individuals aged 5–9 years, 10–14 years, 15–19 years
and 20–24 years are referred to as older children,
young adolescents, older adolescents and young adults,
respectively [6]. Poisson models were used to estimate
the crude LTFU rate. A Lexis expansion was performed
to control for calendar year and time on ART
(<6 months, 6months to <1 year and ≥1 year).
Analyses were adjusted for sex, calendar time and
time on ART. Rate ratios were calculated to investigate
the effect of age at ART initiation on LTFU. A Lexis
expansion was also performed to estimate the effect
of current age on rate of LTFU (age-updated analysis).
LTFU rates were calculated before and after children
transferred to young adolescence, young adolescents
transferred to older adolescence and older adolescents
transferred to young adulthood. Rates of LTFU were
compared in those who started ART in their current
age group to those who started ART in the previous
age group.
Ethics
The requirement for a formal ethical review and individual
consent from patients to use clinical data was waived by
the Medical Research Council of Zimbabwe as anonymized
data were used and no personal identification information
was collected.
Results
Characteristics of the cohort
A total of 2273 individuals were included in the analysis. Of
these, 1013 (37%), 875 (33%) and 385 (16%) initiated ART
at the age of 5–9, 10–14 and 15–19 years, respectively
(Table 1). A total of 52% of the individuals initiating ART
aged 5–9 years (older children) moved to the young ado-
lescent group before the end of follow-up (Supplementary
Figure 1); 45% and 27% of those starting ART as young
adolescents and older adolescents moved to the next age-
group, that is, to older adolescence and young adulthood,
respectively, over the follow-up period. The number of
males and females were similar in all age-bands, except
for the older adolescents with slightly more females (56%)
(Table 1). A total of 65% of the cohort had WHO Stage III/IV
HIV disease at ART initiation and median CD4 count at ART
initiation was 211 cells/μl.
Rates of loss to follow-up
The cohort was observed for 5571 person years, with
194 (8.4%) individuals’ LTFU, resulting in an overall LTFU
rate of 4.92 (95% CI: 4.37, 5.54) per 100 person-years
(PY). The median follow-up time before LTFU was
1.01 years (IQR 0.41–2.04), and the median age at
LTFU was 13 years (IQR 9–18). The cohort grew larger
with time: there were 229 participants in care in 2005
and 2033 in 2009 (Table 2).
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The effect of current age (age-updated) and age at ART
initiation
The rate of LTFU per 100 PY in those who started ART
aged 5–9, 10–14 and 15–19 years was 4.08 (95% CI
3.37, 4.93), 3.86 (95% CI 3.11, 4.78) and 10.58 (95% CI
8.55, 13.11), respectively. The rate of LTFU per 100 PY
in those currently aged 5–9, 10–14, 15–19 and
20–24 years was 5.07 (95% CI 4.10, 6.26), 2.97 (95% CI
2.37, 3.73), 7.39 (95% CI 6.03, 9.06) and 16.91 (96% CI
11.03, 25.94), respectively (p < 0.001) (Table 3). The
salient difference in findings between these two ana-
lyses is that although young adolescents have statisti-
cally significant lower rates of LTFU than children
(Adjusted Rate Ratio (ARR) 0.63; 95% CI 0.46, 0.86),
those who start ART as young adolescents have similar
rates of LTFU (ARR 0.93; 95% CI 0.70, 1.24) to those
who start ART as children.
The effect of transitioning to the next age group
The rate of LTFU in individuals who started ART as young
children reduced after moving to the young adolescent age
group, ARR = 0.63 (95% CI 0.37, 1.08) (Table 4). In those who
started ART as young adolescents, rates of LTFU were signifi-
cantly higher after moving to being older adolescents,
ARR = 1.54 (95% CI 0.94, 2.55). Similarly, those who started
ART as older adolescents had higher rates of LTFU after transi-
tioning to being young adults, ARR = 1.79 (95% CI 1.05, 3.07).
The effect of age at ART initiation within each age group
In older adolescents, the rate of LTFU among those who
started ART in that age-band was higher compared to
the rate of LTFU in those who started ART at a younger
age (ARR = 1.70 (95% CI 1.05, 2.77)) (Table 5). In young
adolescents, however, there was no evidence that the
Table 1. Description of participants by baseline age group at ART initiation
Characteristics 5–9 years 10–14 years 15–19 years Total
Number 1013 875 385 2273
Female, n (%) 461 (46) 430 (49) 215 (56) 1106 (49)
WHO disease stage 3 or 4, n (%) 657 (65) 577 (66) 239 (62) 1473 (65)
CD4 cells count/mL, median (IQR) 260 (114, 417)
(N = 553)
191 (84, 330)
(N = 429)
163 (33, 255)
(N = 165)
211 (90, 379)
(N = 1147)
Year of ART start, n (%)
2005 107 (11) 85 (10) 37 (10) 229 (10)
2006 171 (17) 131 (15) 32 (8) 334 (15)
2007 226 (22) 194 (22) 75 (19) 495 (22)
2008 259 (26) 215 (25) 95 (25) 569 (25)
2009 250 (25) 250 (29) 146 (38) 646 (28)
Number of person years of follow-up 2624 2153 794 5571
Follow-up time in years per subject, median
(IQR)
2.45 (1.44, 3.64) 2.30 (1.34, 3.43) 1.79 (1.15, 2.74) 2.27 (1.30, 3.44)
IQR = Inter-Quartile Range; ART = antiretroviral therapy.
Table 2. Rates of LTFU by calendar year
Year
Number in care during
the calendar year
Follow-up time
(person years)
Number lost to
follow-up
Rate (95% CI) per 100
person years Crude RR Adjusted RR*
2005 229 107 3 2.81 (0.91, 8.70) 1 1
2006 539 329 14 4.25 (2.52, 7.18) 1.51 (0.43, 5.27) 1.90 (0.54, 86.64)
2007 978 709 26 3.67 (2.50, 5.38) 1.31 (0.40, 4.32) 1.73 (0.52, 5.76)
2008 1497 1156 70 6.05 (4.79, 7.65) 2.16 (0.68, 6.85) 3.07 (0.96, 9.84)
2009 2033 1627 81 4.97(4.00, 6.19) 1.77 (0.56, 5.61) 2.54 (0.79, 8.15)
p-Value 0.169 0.046
*adjusted for sex, current age and time on ART.
LTFU = loss-to-follow-up.
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Table 4. Rates of LTFU before and after transition to next age-band
Age at ART
start
Rate before transition to next
age-band (per 100 person
years), (95% CI)
Rate after transition to next
age-band (per 100 person
years), (95% CI) RR (95% CI), p-value
Adjusted* RR (95% CI),
p-value
Older children
(5–9 years)
5.07 (4.10, 6.26) 2.27 (1.48, 3.48) 0.45 (0.28, 0.72), p = 0.001 0.63 (0.37, 1.08), p = 0.094
Young
adolescents
(10–
14 years)
3.39 (2.59, 4.43) 4.95 (3.44, 7.12) 1.46 (0.93, 2.30), p = 0.100 1.54 (0.94, 2.55), p = 0.089
Older
adolescents
(15–
19 years)
9.54 (7.47, 12.19) 16.26 (10.49, 25.20) 1.70 (1.03, 2.81), p = 0.038 1.79 (1.05, 3.07), p = 0.033
*adjusted for time on ART, sex and calendar year.
LTFU = loss-to-follow-up.
Table 3. Unadjusted and adjusted rate ratios estimates of LTFU comparing young children to other age groups
Effect of current age Effect of age at ART start
Age group
Rate (95% CI) per
100 Person Years Crude RR Adjusted* RR
Rate (95% CI) per
100 Person Years Crude RR Adjusted* RR
Older children
(5–9 years)
5.07 (4.10, 6.26) 1 1 4.08 (3.37, 4.93) 1 1
Young adolescents
(10–14 years)
2.97 (2.37, 3.73) 0.57 (0.43, 0.80) 0.63 (0.46, 0.86) 3.86 (3.11, 4.78) 0.95 (0.71, 1.26) 0.93 (0.70, 1.24)
Older adolescents
(15–19 years)
7.39 (6.03, 9.06) 1.46 (1.09, 1.96) 1.58 (1.17, 2.13) 10.58 (8.55, 13.11) 2.60 (1.95, 3.45) 2.43 (1.82, 3.24)
Young adults
(20–24 years)
16.91 (11.03, 25.94) 3.34 (2.07, 5.38) 3.94 (2.41, 6.46) - - -
p-Value* <0.001 <0.001 <0.001 <0.001
*adjusted for duration of ART, sex and calendar year.
LTFU = loss-to-follow-up.
Table 5. Rates of loss to follow-up in different age groups according to when they started ART
Loss to follow-up
Current age
Rate in those who started ART in
this age group (per 100 person
years)
Rate in those who started ART in a
younger age group (per 100 person
years)
RR (95% CI),
p-value
Adjusted* RR
(95% CI), p-value
Young
adolescents
(10–14 years)
3.39 (2.59, 4.43) 2.27 (1.48, 3.48) 1.49 (0.90, 2.47), p = 0.121 1.33 (0.76, 2.32),
p = 0.315
Older adolescents
(15–19 years)
9.54 (7.47, 12.19) 4.95 (3.44, 7.12) 1.93 (1.24, 2.99), p = 0.003 1.70 (1.05, 2.77),
p = 0.032
*adjusted for time on ART, sex and calendar year.
ART = antiretroviral therapy.
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rate of LTFU depended on the age of ART initiation;
young adolescents initiated on ART as children had
similar rates of LTFU (2.27 per 100 PY) compared to
young adolescents starting ART as young adolescents
(3.39 per 100 PY), ARR = 1.33 (95% CI 0.76, 2.32).
Discussion
The key finding of this cohort study is that there is a
significantly increased risk of LTFU in adolescents. Older
adolescents (15–19 year olds) appear particularly vulner-
able. This age group showed an increased rate of LTFU in all
analyses: those starting ART as young adolescents (10–
14 years) had a 1.5 times higher rate of LTFU after moving
into the 15–19 age group; adolescents starting ART aged
15–19 had an increased rate of LTFU compared to adoles-
cents of the same age established on ART at an earlier age;
and moving from adolescence into young adulthood
increased the risk of LTFU by nearly twofold.
Chronic care services have long recognized problems
with retention in care among chronically ill children during
the transitional period between childhood to adulthood
[7,8]. Data from high-income countries show that adoles-
cents living with HIV are at increased risk of LTFU and poor
adherence when reaching young adulthood. In the UK,
young adults aged 15–24 years had an increased risk of
LTFU compared to older adults [9]. A study from the US
showed that the risk of advanced immunosuppression and
detectable viraemia increased significantly as patients grew
older notably at ages 15–19 and older [10]. These data are
in line with experience from low-income countries where
clinicians have reported problems with adherence and poor
clinic retention among HIV-infected adolescents [11].
However, most cohort studies to date have failed to show
an increased risk of LTFU among adolescents in low
resource settings [4,5,12]. The discrepancies between anec-
dotal evidence and cohort analysis performed to date may
be partly related to methodological issues [4].
Cohort studies and programmatic reporting have often
lumped HIV-infected children and adolescents together
[13,14]. Furthermore, analyses categorize individuals by
the age of ART initiation rather than current age and do
not consider the impact of the transition from childhood to
adolescence and adulthood on care outcomes [4]. Unlike in
adults, where behaviour and cognitive function are rela-
tively stable across 5–10 year age-bands, adolescence is a
critical phase of development accompanied by rapid physi-
cal, psychosocial and emotional changes, which influence
health-related behaviour and outcomes [15,16]. Cognitive,
social and psychological functioning is therefore not only
extremely heterogeneous across the age range of
0–24 years, but is strongly associated with factors that
may influence HIV care outcomes. For example, the stage
of development influences the extent to which parents and
guardians are involved in healthcare. Children are usually
accompanied to clinic appointments by their parents or
guardians who also facilitate adherence to medication. In
contrast, adolescents are expected to take responsibility for
their own health when they may not have fully acquired
the skills required to manage a chronic illness [17,18].
Disclosure of HIV status to the child and adolescent
depends upon their emotional maturity and their ability
to process information appropriately, and disclosure status
is strongly associated with outcomes [19,20]. Age also mat-
ters when it comes to navigating a complex social environ-
ment, as is often the case for children growing up with HIV.
Peer relationships become highly influential as children
approach adolescence [21]. Children and adolescents living
with chronic medical conditions such as HIV often endure
social isolation [22] and experience external as well as
internalized stigma as a result of feeling different from
others [23,24]. Social pressures to “fit in” may place this
population at high risk for engaging in health risk behaviour
including dropping out of HIV care.
The age-related rapid change of cognitive, psychosocial
and psychomotor development calls for an analytic
approach using narrow age-bands such as those used in
our study. Data for children and adolescents have been
analysed in a variety of ways categorizing children and
adolescents into variably aggregated age-bands in compar-
ison with adults, for example, adolescents (10–19 years)
[25], children (<15 years) [14] and youth (15–24 years) [26].
Careful consideration to decide how best to categorize
persons in the 0–24 year age group is needed. An optimized
and standardized approach is required to minimize hetero-
geneity in findings. We propose the use of five year age-
bands to separate older children (5–9 years), from young
adolescents (10–14 years), older adolescents (15–19 years)
and young adults (20–24 years) [12]. Furthermore, most
analyses classify individuals into age-bands based on age
at initiation of ART. It is only a matter of time before an
individual moves into the next age-band but this is not
considered in standard cohort analyses, which then results
in misclassification. Age-updated analysis taking into
account the current age of individual should therefore be
the standard when conducting cohort analysis among chil-
dren and adolescents.
The strength of the analysis is the number of children,
adolescents and young adults included and the use of the
data from a public-sector health setting, which makes the
findings broadly generalizable. We utilized a novel approach
to investigate outcomes using age-updated analyses that
enables assessment of the effect of changing age on out-
comes in childhood disease. Unlike in adults, this approach
is critical for adolescence where there are rapid develop-
mental changes with increasing age, which substantially
impact outcomes. These are not taken into account in
most studies to date, as age is not usually updated in theses
cohort analyses [5,25,12–14].
Our study has several limitations. The study used
retrospective routinely collected data, possibly misclas-
sifying death as LTFU. A high proportion of CD4 counts
at ART initiation was missing. This meant that the ana-
lysis did not take the degree of immunodeficiency into
account. Adjustment for WHO stage made no substan-
tive difference to the results (data not shown). The high
proportion of missing CD4 counts was likely due to a
combination of CD4 counts not being performed and
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not recorded in a routine health programme from which
these data were obtained. Data on mode of infection
were not available. However, gender was relatively
balanced across age groups suggesting perinatal infec-
tion as the most likely route of infection for most of
these children. Among the older adolescents, some
might have been infected sexually, as there is a slight
increase in the proportion of girls (56%) among the
15–19 year olds. The data were censored at the end
of 2010 and thus might be considered “outdated”.
However, Zimbabwe has had a much earlier onset and
severe HIV epidemic with antenatal HIV prevalence
peaking in 1997 [27]. As a result, large numbers of
adolescents were already on ART in Zimbabwe during
the period of this analysis (2004–2011, 5). Therefore,
the findings have strong relevance to other countries
with later onset epidemics, which are only now seeing
comparable numbers of older children and adolescents
who have grown up with HIV infection presenting to
healthcare services. CD4 thresholds have changed over
the last decade, with the most recent 2015 WHO guide-
lines recommending treatment of all HIV-infected indi-
viduals regardless of CD4 cell counts [28]. This policy
will hopefully change the risks of morbidity and mortal-
ity in children and adolescents starting on ART now and
in the future. Whether early start of ART changes the
risk of LTFU remains to be seen [29,30]. Increasing
numbers of HIV-infected children are surviving into ado-
lescence and beyond making these findings and the
novel analysis approach highly relevant for 2017.
To our knowledge, this is the first age-updated analysis
investigating critical periods of transition across the age spec-
trum of 5–19 year olds using narrow five-year age-bands. We
recommend this as an approach to investigate outcomes in
children and adolescents with chronic disease, including HIV.
Standardized analysis, taking into account the heterogeneity
within children and adolescents, will facilitate high-quality
studies. Older adolescents are at increased risk of LTFU even
when they reach adulthood and importantly adolescents are
the only age group in which HIV-related mortality is still rising
[31]. Therefore, interventions specifically targeted at this age
group are a high priority [3,32]. Thus far few evidence-based
interventions exist targeting HIV-infected adolescents [33].
Systematic reviews assessing intervention among children
and adolescents with other chronic diseases have also high-
lighted the need for more data and better quality studies
[7,34,35]. Standardized and widely agreed methodology will
foster high-quality research and add weight to the evidence to
focus on adolescents living with HIV.
In summary, this study shows an increased risk of attrition
of HIV-infected older adolescents and underscores the impor-
tance of accounting for changing in age in the analysis.
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